Cost-Effectiveness Analysis Of The 13-Valent And 20-Valent Pneumococcal Conjugate Vaccine In The Kazakh Adult Population
Author(s)
Thea Paoula Nassar, MSc1, Liping Huang, MSc, MD2, Kamila Tuyakbayeva, MPP, Other3, Aigerim Shaimagambetova, MPH3, Zhadyra Bizhanova, MD3, Svetlana Struch, MD4.
1Pfizer UK, England, United Kingdom, 2Pfizer, Washington Crossing, PA, USA, 3Pfizer, Almaty, Kazakhstan, 4Pfizer, Moscow, Russian Federation.
1Pfizer UK, England, United Kingdom, 2Pfizer, Washington Crossing, PA, USA, 3Pfizer, Almaty, Kazakhstan, 4Pfizer, Moscow, Russian Federation.
OBJECTIVES: Although national guidelines recommend pneumococcal vaccination for adults in Kazakhstan, the 13-valent pneumococcal conjugate vaccine (PCV13) is not included in the adult national immunization program (NIP), resulting in low vaccination rates in this age group. With newer availability of PCV20, this study aimed to evaluate the cost-effectiveness of implementing PCV13 or PCV20 compared to no vaccination for the prevention of pneumococcal disease (PD) in Kazakhstan’s adult population.
METHODS: A probabilistic Markov model capturing the lifetime risk of clinical outcomes and economic costs of PD in the defined population was used to evaluate the cost-effectiveness of a single dose of PCV13 or PCV20 vs. no vaccination. The model population is stratified based on age and risk profile (i.e., low, moderate, or high-risk of disease) in adults ≥ 18 years. Cost and health outcomes were discounted at 5% annually from a payer perspective. Epidemiologic parameters, serotype coverage, costs, vaccines effectiveness and population inputs were obtained from Kazakhstan-specific sources and relevant literature.
RESULTS: A 15% vaccination coverage was evaluated among adults aged 50-64 years with chronic/immunocompromising conditions and all adults aged 65+ years. Compared to no vaccination, PCV13 and PCV20 were estimated to avert 21,422 and 25,739 PD cases, and 604 and 727 deaths, respectively. Consequently, PCV13 and PCV20 were projected to save 3.76 million KZT and 4.55 million KZT in direct medical costs, with total budget impacts of 4.55 million KZT and 5.76 million KZT. The incremental cost-effectiveness ratio (ICER) of PCV13 and PCV20 versus no vaccination was estimated as 243,307 KZT and 310,985 KZT per quality adjusted life year (QALY), respectively, both below the established willingness-to-pay threshold (55% GDP per capita).
CONCLUSIONS: Vaccinating with a single dose of PCV13 or PCV20 in targeted adult population in Kazakhstan is expected to significantly reduce clinical and economic burdens associated with PD.
METHODS: A probabilistic Markov model capturing the lifetime risk of clinical outcomes and economic costs of PD in the defined population was used to evaluate the cost-effectiveness of a single dose of PCV13 or PCV20 vs. no vaccination. The model population is stratified based on age and risk profile (i.e., low, moderate, or high-risk of disease) in adults ≥ 18 years. Cost and health outcomes were discounted at 5% annually from a payer perspective. Epidemiologic parameters, serotype coverage, costs, vaccines effectiveness and population inputs were obtained from Kazakhstan-specific sources and relevant literature.
RESULTS: A 15% vaccination coverage was evaluated among adults aged 50-64 years with chronic/immunocompromising conditions and all adults aged 65+ years. Compared to no vaccination, PCV13 and PCV20 were estimated to avert 21,422 and 25,739 PD cases, and 604 and 727 deaths, respectively. Consequently, PCV13 and PCV20 were projected to save 3.76 million KZT and 4.55 million KZT in direct medical costs, with total budget impacts of 4.55 million KZT and 5.76 million KZT. The incremental cost-effectiveness ratio (ICER) of PCV13 and PCV20 versus no vaccination was estimated as 243,307 KZT and 310,985 KZT per quality adjusted life year (QALY), respectively, both below the established willingness-to-pay threshold (55% GDP per capita).
CONCLUSIONS: Vaccinating with a single dose of PCV13 or PCV20 in targeted adult population in Kazakhstan is expected to significantly reduce clinical and economic burdens associated with PD.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH52
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Public Health
Disease
Vaccines